Flossbach Von Storch SE Purchases 77,554 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Flossbach Von Storch SE grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,412,839 shares of the medical research company's stock after buying an additional 77,554 shares during the quarter. Thermo Fisher Scientific accounts for 3.0% of Flossbach Von Storch SE's investment portfolio, making the stock its 15th biggest position. Flossbach Von Storch SE owned 0.37% of Thermo Fisher Scientific worth $703,029,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. One Charles Private Wealth Services LLC increased its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock valued at $260,000 after purchasing an additional 20 shares during the last quarter. Holderness Investments Co. increased its stake in Thermo Fisher Scientific by 1.7% in the fourth quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock valued at $664,000 after purchasing an additional 21 shares during the last quarter. Port Capital LLC grew its position in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after acquiring an additional 22 shares during the last quarter. Finally, Clark Capital Management Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.5% during the fourth quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock worth $2,312,000 after acquiring an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 1.6%

Shares of TMO stock traded down $6.70 on Wednesday, reaching $419.47. 2,735,091 shares of the stock were exchanged, compared to its average volume of 1,985,486. The stock has a 50 day moving average price of $409.11 and a 200 day moving average price of $478.29. The stock has a market cap of $158.35 billion, a PE ratio of 24.60, a P/E/G ratio of 2.23 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the firm posted $5.11 EPS. The business's revenue was up .2% on a year-over-year basis. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. Thermo Fisher Scientific's payout ratio is 10.09%.

Wall Street Analyst Weigh In

TMO has been the subject of several recent research reports. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Evercore ISI cut their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday. Argus cut their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Finally, Scotiabank cut their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday, April 25th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $601.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.